Enterprise Value
293.5B
Cash
6.378B
Avg Qtr Burn
N/A
Short % of Float
0.62%
Insider Ownership
0.09%
Institutional Own.
77.65%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PADCEV® (enfortumab vedotin-ejfv) + KEYTRUDA® (pembrolizumab) Details Solid tumor/s, Cancer, Urothelial cancer | Approved Update | |
GARDASIL 9 Details Human Papillomavirus 9-valent Vaccine, Human papillomavirus | Approved Update | |
M-M-R®II, VARIVAX®, and ProQuad® Details Vaccine, Viral infection | Approved Update | |
KEYTRUDA Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | Approved Update | |
PREVYMIS™ (letermovir) Details Cytomegalovirus, Viral infection | Approved Quarterly sales | |
TUKYSA (Tucatinib) Details Solid tumor/s, Colorectal cancer , Cancer, Metastatic colorectal cancer | Approved Quarterly sales | |
LYNPARZA(olaparib) + abi/pred Details Solid tumor/s, Cancer, Castration-resistant prostate cancer | Approved Quarterly sales | |
KEYTRUDA in comb w/chemotherapy Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | Approved Quarterly sales | |
KEYTRUDA+ chemotherapy Details Cancer, Biliary Tract Cancer | Approved Quarterly sales | |
KEYTRUDA+ trastuzumab+ chemotherapy Details Cancer, Gastroesophageal adenocarcinomas, Gastric cancer | Approved Quarterly sales | |
ERVEBO Details Ebola | Approved Quarterly sales | |
KEYTRUDA+ chemotherapy Details Cancer, Gastroesophageal adenocarcinomas, Gastric cancer | Approved Quarterly sales | |
Sotatercept Details Pulmonary arterial hypertension | PDUFA Approval decision | |
KEYTRUDA in comb w/ EBRT + brachytherapy Details Cancer, Cervical cancer | PDUFA Approval decision | |
WELIREG® (belzutifan) Details Renal cell carcinoma | PDUFA Approval decision | |
Gefapixant (MK-7264) Details Chronic cough | PDUFA Approval decision | |
Bomedemstat Details Thrombocythemia | Phase 3 Data readout | |
KEYTRUDA+pemetrexed Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | Phase 3 Data readout | |
KEYTRUDA +carboplatin + paclitaxel Details Solid tumor/s, Cancer, Carcinoma , Endometrial cancer | Phase 3 Data readout | |
KEYTRUDA+ Padcev (enfortumab vedotin) Details Cancer, Urothelial carcinoma | Phase 3 Data readout | |
MK-0616 Details Cardiovascular disease , Hypercholesterolemia | Phase 3 Data readout | |
Islatravir+ Doravirine Details Viral infection, Human immunodeficiency virus | Phase 3 Data readout | |
LAGEVRIO™ (molnupiravir) Details Viral infection, COVID-19 | Phase 3 Data readout | |
KEYTRUDA Details Solid tumor/s, Cancer, Urothelial carcinoma | Phase 3 Update | |
KEYTRUDA +LENVIMA® (lenvatinib) Details Cancer, Non-small cell lung carcinoma | Phase 3 Update | |
KEYTRUDA+ chemotherapy Details Cancer, Mesothelioma, Malignant pleural/peritoneal mesothelioma | Phase 3 Update | |
KEYTRUDA + LENVIMA Details Renal cell carcinoma, Cancer | Phase 3 Update | |
V116 Details Pneumococcal Conjugate Vaccine | Phase 3 Update | |
KEYTRUDA Details Solid tumor/s, Cancer, ER+/HER2- breast cancer | Phase 3 Update | |
KEYTRUDA Details Renal cell carcinoma, Cancer | Phase 3 Update | |
KEYTRUDA +LENVIMA® (lenvatinib) Details Cancer, Carcinoma , Endometrial cancer | Phase 3 Update | |
PRA023 (Anti-TL1A mAb) Details Crohns disease | Phase 3 Initiation | |
MK-0616 Details Hypercholesterolemia | Phase 3 Initiation | |
Efinopegdutide (MK-6024) Details Non-Alcoholic Fatty Liver Disease, Liver disease | Phase 2b Initiation | |
Bomedemstat Details Myelofibrosis | Phase 2 Data readout | |
PRA023 (Anti-TL1A mAb) Copy Details Autoimmune disease, Systemic sclerosis | Phase 2 Data readout | |
PRA023 (Anti-TL1A mAb) Details Systemic sclerosis, Autoimmune disease | Phase 2 Data readout | |
Belzutifan + cabozantinib Details Cancer, Renal cell carcinoma | Phase 2 Update | |
MK-7240 (PRA023) (Anti-TL1A mAb) Details Irritable bowel syndrome, Crohns disease, Ulcerative colitis | Phase 2 Update | |
PRA052 Details Inflammatory bowel disease | Phase 1 Data readout | |
KEYTRUDA + LENVIMA Details Cancer, Head and neck squamous cell carcinoma | Failed Discontinued | |
KEYTRUDA+ enzalutamide + androgen deprivation therapy (ADT) Details Solid tumor/s, Cancer, Castration-resistant prostate cancer | Failed Discontinued |